NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders

References

• Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug—Sernyl. Arch Neurol Psychiatry 1959; 81: 363-9.
   Google Scholar
• Zukin SR, Zukin RS. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979; 76: 5372-6.
   Google Scholar
• Cotman CW, Kahle JS, Miller SE, Ulas J, Bridges RJ. Excitatory amino acid neurotransmission. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven, 1995: 75-86.
   Google Scholar
• Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci 1996; 17: 348-55.
   Google Scholar
• Kornhuber J, Mack-Burkhardt F, Riederer P. Regional distribution of [3H]MK-801 binding sites in the human brain. Brain Res 1989; 489: 397-9.
   Google Scholar
• Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by W-methyl-aspartate. Br J Pharmacol 1983; 79: 565-75.
   Google Scholar
• Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol 1994; 4: 389-99.
   Google Scholar
• Yakel JL. Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. Trends Pharmacol Sci 1997; 18: 124-34.
   Google Scholar
• Wheal HV, Chen Y, Mitchell J, Schachner M, Maerz W, Wie-land H, et al. Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity. Prog Neurobiol 1998; 55: 611-40.
   Google Scholar
• Sudhof TC, Rizo J. Synaptotagmins: C2-domain proteins that regulate membrane traffic. Neuron 1996; 17: 379-88.
   Google Scholar
• Snyder SH, Dawson TH. Nitric oxide and related substances as neural messengers. In: Bloom FE, Kupfer DJ, eds. Psycho-pharmacology: the fourth generation of progress. New York: Raven, 1995: 609-18.
   Google Scholar
• Ciabarra AM, Sullivan JM, Gahn LG, Pecht G, Heinemann S, Sevarino KA. Cloning and characterization of x-1: a devel-opmentally regulated member of a novel class of the iono-tropic glutamate receptor family. J Neurosci 1995; 15: 6498-508.
   Google Scholar
• Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325: 529-31.
   Google Scholar
• D'Souza DC, Charney DS, Krystal JH. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev 1995; 1: 227-60.
   Google Scholar
• Honer M, Benke D, Laube B, Kuhse J, Heckendorn R, All-geier H, et al. Differentiation of glycine antagonist sites of W-methyl-D-aspartate receptor subtypes: preferential interaction of CGP 61594 with NR1/2B receptors. J Biol Chem 1998; 273: 11158-63.
   Google Scholar
• Sucher NJ, Akbarian S, Chi CL, Leclerc CL, Awobuluyi M, Deitcher DL, et al. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci 1995; 15: 6509-20.
   Google Scholar
• Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M. Differential sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 1993; 4: 687-90.
   Google Scholar
• Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia— implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13: 272-6.
   Google Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
   Google Scholar
• Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia: experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm Gen Sect 1993; 92: 57-65.
   Google Scholar
• Krystal JH, Belger A, Abi-Saab W, Moghaddam B, Charney DS, Anand A, et al. Glutamatergic contributions to cognitive dysfunction in schizophrenia. In: Harvey PD, Sharma T, eds. Cognitive functioning in schizophrenia. London: Oxford University Press [In press].
   Google Scholar
• Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 1998; 155: 726-32.
   Google Scholar
• Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 1996; 3: 241-53.
   Google Scholar
• Heresco-Levy U, Javitt DC. The role ofW-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the patho-physiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 1998; 8: 141-52.
   Google Scholar
• Rison RA, Stanton PK. Long-term potentiation and W-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Neurosci Biobehav Rev 1995; 19: 533-52.
   Google Scholar
• Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology 1998; 51(2, suppl 2): S30-5.
   Google Scholar
• Soderling TR. Calcium-dependent protein kinases in learning and memory. Adv Second Messenger Phosphoprotein Res 1995; 30: 175-89.
   Google Scholar
• Miyamoto E, Fukunaga K. A role of Ca2+/calmodulin-dependent protein kinase II in the induction of long-term potentiation in hippocampal CA1 area. Neurosci Res 1996; 24: 117-22.
   Google Scholar
• Lisman J, Malenka RC, Nicoll RA, Malinow R. Learning mechanisms: the case for CaM-KII. Science 1997; 276: 2001-2.
   Google Scholar
• Morris RG, Frey U. Hippocampal synaptic plasticity: role in spatial learning or the automatic recording of attended experience? Philos Trans R Soc Lond B Biol Sci 1997; 352: 1489-503.
   Google Scholar
• Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-43.
   Google Scholar
• Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC. Keta-mine: behavioral effects of subanesthetic doses. J Clin Psy-chopharmacol 1985; 5: 70-7.
   Google Scholar
• Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompeti-tive NMDA antagonist, ketamine, in humans: psychotomi-metic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
   Google Scholar
• Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuro-psychopharmacology 1996; 14: 301-7.
   Google Scholar
• LaPorte DJ, Lahti AC, Koffel B, Tamminga CA. Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients. J Psychiatr Res 1996; 30: 321-30.
   Google Scholar
• Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of W-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992; 260: 1209-13.
   Google Scholar
• Palmer AM, Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 1990; 4: 2745-52.
   Google Scholar
• Schuster GM, Schmidt WJ. D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. Eur J Pharmacol 1992; 224: 97-8.
   Google Scholar
• Fishkin RJ, Ince ES, Carlezon WA Jr, Dunn RW. D-cyclo-serine attenuates scopolamine-induced learning and memory deficits in rats. Behav Neural Biol 1993; 59: 150-7.
   Google Scholar
• Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995; 8: 226-30.
   Google Scholar
• Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996; 46: 420-4.
   Google Scholar
• Tsai GE, Falk WE, Gunther J. A preliminary study of D-cycloserine treatment in Alzheimer's disease. J Neuropsychi-atry Clin Neurosci 1998; 10: 224-6.
   Google Scholar
• Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 1994; 8: 198-205.
   Google Scholar
• Krystal JH, D'Souza DC. D-serine and the therapeutic challenge posed by the W-methyl-D-aspartate antagonist model of schizophrenia. Biol Psychiatry 1998; 44: 1075-6.
   Google Scholar
• Procter AW, Stratmann GC, Francis PT, Lowe SL, Bertolucci PH, Bowen DM. Characterisation of the glycine modulatory site of the W-methyl-D-aspartate receptor-ionophore complex in human brain. J Neurochem 1991; 56: 299-310.
   Google Scholar
• Del Bel EA, Slater P. Binding to the glycine site of the NMDA receptor complex in brains of patients with Alzheimer's disease. Neurosci Lett 1991; 131: 75-8.
   Google Scholar
• Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilita-tive effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 1998; 18: 2748-63.
   Google Scholar
• Lynch G, Kessler M, Rogers G, Ambros-Ingerson J, Granger R, Schehr RS. Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol 1996; 11: 13-9.
   Google Scholar
• Foster NL, Giordani B, Mellow A, Aronson S, Berent S. Memory effects of low-dose ketamine in Alzheimer's disease. Presented at the 43rd annual meeting ofthe American Academy of Neurology, Boston, April 1991.
   Google Scholar
• Moghaddam B, Adams B, Verma A, Daly D. Activation of glu-tamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-7.
   Google Scholar
• Blanchard BJ, Konopka G, Russell M, Ingram VM. Mechanism and prevention of neurotoxicity caused by p-amyloid peptides: relation to Alzheimer's disease. Brain Res 1997; 776: 40-50.
   Google Scholar
• Carlson MD, Penney JB Jr, Young AB. NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiol Aging 1993; 14: 343-52.
   Google Scholar
• Ulas J, Brunner LC, Geddes JW, Choe W, Cotman CW. W-methyl-D-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease. Neuroscience 1992; 49: 45-61.
   Google Scholar
• Jansen KL, Faull RL, Dragunow M, Synek BL. Alzheimer's disease: changes in hippocampal W-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors— an autoradiographic study. Neuroscience 1990; 39: 613-27.
   Google Scholar
• Scheuer K, Maras A, Gattaz WF, Cairns N, Forstl H, Muller WE. Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. Dementia 1996; 7: 210-4.
   Google Scholar
• Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegen-eration in Alzheimer disease: new hypothesis and new therapeutic strategies. Arch Neurol 1997; 54: 1234-40.
   Google Scholar
• Wu J, Anwyl R, Rowan MJ. p-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 1995; 6: 2409-13.
   Google Scholar
• Koh JY, Yang LL, Cotman CW. p-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990; 533: 315-20.
   Google Scholar
• Willoughby DA, Rozovsky I, Lo AC, Finch CE. p-Amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. J Mol Neurosci 1995; 6: 257-76.
   Google Scholar
• Millan MJ, Seguin L. Chemically-diverse ligands at the gly-cine B site coupled to W-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice. Neurosci Lett 1994; 178: 139-43.
   Google Scholar
• Mercadante S. Ketamine in cancer pain: an update. Palliat Med 1996; 10: 225-30.
   Google Scholar
• Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies: what advantages do they offer for the control of pain syndromes? Drugs 1998; 55: 1-4.
   Google Scholar
• Sethna NF, Liu M, Gracely R, Bennett GJ, Max MB. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal cap-saicin in normal subjects. Anesth Analg 1998; 86: 1250-6.
   Google Scholar
• Trujillo KA. Effects of noncompetitive W-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 1995; 13: 301-7.
   Google Scholar
• Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthe-siol Scand 1997; 41: 1124-32.
   Google Scholar
• Warncke T, Stubhaug A, J0rum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain 1997; 72: 99-106.
   Google Scholar
• Rice AC, DeLorenzo RJ. NMDA receptor activation during status epilepticus is required for the development of epilepsy. Brain Res 1998; 782: 240-7.
   Google Scholar
• Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994; 44(11, suppl 8): S14-23.
   Google Scholar
• Feinberg I, Campbell IG, Marrs JC. Intraperitoneal dizocil-pine induces cortical spike-wave seizure discharges in rats. Neurosci Lett 1995; 196: 157-60.
   Google Scholar
• Dingledine R, Hynes MA, King GL. Involvement of W-methyl-D-aspartate receptors in epileptiform bursting in the rat hippocampal slice. J Physiol 1986; 380: 175-89.
   Google Scholar
• Apland JP, Cann FJ. Anticonvulsant effects of memantine and MK-801 in guinea pig hippocampal slices. Brain Res Bull 1995; 37: 311-6.
   Google Scholar
• Applegate CD, Samoriski GM, Ozduman K. Effects of val-proate, phenytoin, and MK-801 in a novel model of epilepto-genesis. Epilepsia 1997; 38: 631-6.
   Google Scholar
• Fountain NB, Bear J, Bertram EH III, Lothman EW. Responses of deep entorhinal cortex are epileptiform in an elec-trogenic rat model of chronic temporal lobe epilepsy. J Neuro-physiol 1998; 80: 230-40.
   Google Scholar
• Kubova H, Mares P. Suppression of cortical epileptic afterdis-charges by ketamine is not stable during ontogenesis in rats. Pharmacol Biochem Behav 1995; 52: 489-92.
   Google Scholar
• Sagratella S. NMDA antagonists: antiepileptic-neuropro-tective drugs with diversified neuropharmacological profiles. Pharmacol Res 1995; 32: 1-13.
   Google Scholar
• Davies JA. Remacemide hydrochloride: a novel antiepileptic agent. Gen Pharmacol 1997; 28: 499-502.
   Google Scholar
• Subramaniam S, Donevan SD, Rogawski MA. Block of the W-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther 1996; 276: 161-8.
   Google Scholar
• White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor. Epi-lepsyRes 1995; 20: 41-8.
   Google Scholar
• Theodore WH, Albert P, Stertz B, Malow B, Ko D, White S, et al. Felbamate monotherapy: implications for antiepileptic drug development. Epilepsia 1995; 36: 1105-10.
   Google Scholar
• Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Fracko-wiak RS. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160: 179-86.
   Google Scholar
• Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995; 52: 341-51.
   Google Scholar
• Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, et al. Interactive effects ofsubanes-thetic ketamine and haloperidol. Psychopharmacology [In press].
   Google Scholar
• Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, et al. Interactive effects of su-banesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998; 135: 213-29.
   Google Scholar
• Adler CM, Malhotra AK, Goldberg T, Elman I, Pickar D, Breier A. A comparison of ketamine-induced and schizophrenic thought disorder. Presented at the 53rd annual meeting of the Society of Biological Psychiatry, Toronto, May 1998.
   Google Scholar
• Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31(suppl 2): 104-9.
   Google Scholar
• Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 1998; 55: 354-60.
   Google Scholar
• Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry [In press].
   Google Scholar
• Krystal JH, Belger A, Kirino E, Madonick S, Gatenby CJ, Gore JC, et al. Modulation of cingulate activation to infrequent visual targets by ketamine: a functional MRI study. Presented at the 28th annual meeting of the Society for Neu-roscience, Los Angeles, November 1998.
   Google Scholar
• Belger A, Kirino E, McCarthy G, Gore JC, Krystal JH. Assessment of prefrontal activation by infrequent visual targets and non-target novel stimuli in schizophrenia: a functional MRI study. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kona, Hawaii, December 1997.
   Google Scholar
• Gruzelier J, Seymour K, Wilson L, Jolley A, Hirsch S. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988; 45: 623-9.
   Google Scholar
• Kolb B, Whishaw IQ. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. J Nerv Ment Dis 1983; 171: 435-43.
   Google Scholar
• Brebion G, Amador X, Smith MJ, Gorman JM. Mechanisms underlying memory impairment in schizophrenia. Psychol Med 1997; 27: 383-93.
   Google Scholar
• Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts W-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42: 664-8.
   Google Scholar
• D'Souza DC, Gil R, Belger A, Zimmerman L, Tracy L, Larvey K, et al. Glycine-ketamine interactions in healthy humans. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kona, Hawaii, December 1997.
   Google Scholar
• Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH. Lamotrigine reduces the psychotomimetic— but not the mood elevating— effects ofketamine in humans. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kona, Hawaii, December 1997.
   Google Scholar
• Krystal J, Karper L, D'Souza DC, Webb E, Bennett A, Abi-Dargham A, et al. Differentiating NMDA dysregulation in schizophrenia and alcoholism using ketamine. Presented at the 5th International Congress on Schizophrenia Research, Warm Springs, Virginia, April 1995.
   Google Scholar
• Freund G, Anderson KJ. Glutamate receptors in the frontal cortex of alcoholics. Alcohol Clin Exp Res 1996; 20: 1165-72.
   Google Scholar
• Krystal JH, Webb E, Petrakis I, Cooney N, Namanworth S, Trevisan L, et al. Blunted NMDA antagonist responses in recently detoxified alcoholics. Presented at the 1995 meeting of the Research Society on Alcoholism, Steamboat Springs, Colorado, June 1995.
   Google Scholar
• Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996; 16: 19-30.
   Google Scholar
• Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong LL, Ho TH, et al. Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? Mol Psychiatry 1998; 3: 32-7.
   Google Scholar
• Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990; 85: 119-46.
   Google Scholar
• Krystal JH, Abi-Dargham A, Laruelle M, Moghaddam B. Pharmacologic model psychoses. In: Charney DS, Nestler E, Bunney BS, eds. Neurobiology of mental illness. New York: Oxford University Press, 1992: 214-224.
   Google Scholar
• Kornhuber J, Weller M. Psychotogenicity and W-methyl-D-aspartate receptor antagonism: implications for neuroprotec-tive pharmacotherapy. Biol Psychiatry 1997; 41: 135-44.
   Google Scholar
• Greenamyre JT, O'Brien CF. W-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991; 48: 977-81.
   Google Scholar
• Olney JW, Price MT, Labruyere J, Salles KS, Frierdich G, Mueller M, et al. Anti-parkinsonian agents are phencyclidine agonists and W-methyl-aspartate antagonists. Eur J Pharmacol 1987; 142: 319-20.
   Google Scholar
• Anonymous. Parkinson's disease and amantadine hydrochloride. JAMA 1969; 208: 1180-1.
   Google Scholar
• Parkes JD, Calver DM, Zilkha KJ, Knill-Jones RP. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1970; 1: 259-62.
   Google Scholar
• Verhagen Metman L, Del Dotto P, Natte R, Van den Munck-hof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998; 51: 203-6.
   Google Scholar
• Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide hydro-chloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994; 35: 655-61.
   Google Scholar
• Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of meman-tine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neur TransmPark Dis Dement Sect 1992; 4: 277-82.
   Google Scholar
• Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, et al. Amantadine treatment is an independent predictor ofimproved survival in Parkinson's disease. Neurology 1996; 46: 1551-6.
   Google Scholar
• Brooks S, Kaur S, Starr BS, Starr MS. Motor actions of eli-prodil in the normal and monoamine-depleted mouse: a role in the treatment ofParkinson's disease? J Neur Transm Gen Sect 1996; 103: 737-48.
   Google Scholar
• Weihmuller FB, Ulas J, Nguyen L, Cotman CW, Marshall JF. Elevated NMDA receptors in parkinsonian striatum. Neur-oreport 1992; 3: 977-80.
   Google Scholar
• Ulas J, Weihmuller FB, Brunner LC, Joyce JN, Marshall JF, Cotman CW. Selective increase of NMDA-sensitive gluta-mate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J Neurosci 1994; 14: 6317-24.
   Google Scholar
• Menegoz M, Lau LF, Herve D, Huganir RL, Girault JA. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 1995; 7: 125-8.
   Google Scholar
• Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neurobiol 1996; 12: 73-94.
   Google Scholar
• Hershey T, Black KJ, Stambuk MK, Carl JL, McGee-Minnich LA, Perlmutter JS. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA 1998; 95: 12016-21.
   Google Scholar
• Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346: 1383-7.
   Google Scholar
• Benabid AL, Pollak P, Gervason C, Hoffmann D, Gao DM, Hommel M, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403-6.
   Google Scholar
• Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinet-ics and effects on dopamine turnover. J Neural Transm Suppl 1995; 46: 97-105.
   Google Scholar
• Schmidt CJ, Fadayel GM. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 1996; 277: 1541-9.
   Google Scholar
• Moghaddam B, Bolinao ML. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse 1994; 18: 337-42.
   Google Scholar
• Gusella JF, MacDonald ME. Huntingtin: a single bait hooks many species. Curr Opin Neurobiol 1998; 8: 425-30.
   Google Scholar
• Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983; 306: 234-8.
   Google Scholar
• Calabresi P, Centonze D, Pisani A, Sancesario G, Gubellini P, Marfia GA, et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol 1998; 43: 586-97.
   Google Scholar
• Kosinski CM, Cha JH, Young AB, Persichetti F, MacDonald M, Gusella JF, et al. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and in-terneurons. Exp Neurol 1997; 144: 239-47.
   Google Scholar
• Wichmann T, DeLong MR. Functional and pathophysiologi-cal models of the basal ganglia. Curr Opin Neurobiol 1996; 6: 751-8.
   Google Scholar
• Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988; 85: 5733-7.
   Google Scholar
• Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clin Neuropharmacol 1992; 15: 148-51.
   Google Scholar
• Dure LS IV, Young AB, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann Neurol 1991; 30: 785-93.
   Google Scholar
• Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996; 11: 273-7.
   Google Scholar
• Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJ, Hariharan M, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997; 49: 153-61.
   Google Scholar
• Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989; 243: 1721-4.
   Google Scholar
• Grant KA, Lovinger DM. Cellular and behavioral neurobiol-ogy of alcohol: receptor-mediated neuronal processes. Clin Neurosci 1995; 3: 155-64.
   Google Scholar
• Holter SM, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 1996; 314: R1-2.
   Google Scholar
• Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995; 152: 332-40.
   Google Scholar
• Krystal JH, Petrakis IL, D'Souza DC, Trevisan L, Krasnicki S, Charney DS. Interactive effects of high dose intravenous glycine and oral D-cycloserine in healthy human subjects. Presented at the 1997 annual meeting of the Society of Biological Psychiatry, San Diego, May 1997.
   Google Scholar
• Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by Acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-80.
   Google Scholar
• Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, et al. Comparison ofAcamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438-42.
   Google Scholar
• Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989; 32: 607-11.
   Google Scholar
• Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur J Pharmacol 1996; 307: 251-7.
   Google Scholar
• Rasmussen K, Kendrick WT, Kogan JH, Aghajanian GK. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsycho-pharmacology 1996; 15: 497-505.
   Google Scholar
• Rasmussen K. The role of the locus coeruleus and W-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Neuropsychopharmacology 1995; 13: 295-300.
   Google Scholar
• Rasmussen K, Fuller RW, Stockton ME, Perry KW, Swinford RM, Ornstein PL. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 1991; 197: 9-16.
   Google Scholar
• Rasmussen K, Krystal JH, Aghajanian GK. Excitatory amino acids and morphine withdrawal: differential effects of central and peripheral kynurenic acid administration. Psycho-pharmacology 1991; 105: 508-12.
   Google Scholar
• Aghajanian GK, Kogan JH, Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res 1994; 636: 126-30.
   Google Scholar
• Rasmussen K, Aghajanian GK. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res 1989; 505: 346-50.
   Google Scholar
• Vandergriff J, Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 1999; 38: 217-22.
   Google Scholar
• Ushijima I, Kobayashi T, Suetsugi M, Watanabe K, Yamada M, Yamaguchi K. Cocaine: evidence for NMDA-, p-carboline- and dopaminergic-mediated seizures in mice. Brain Res 1998; 797: 347-50.
   Google Scholar
• Post RM, Kopanda RT. Cocaine, kindling, and psychosis. Am J Psychiatry 1976; 133: 627-34.
   Google Scholar
• Kalivas PW, Duffy P. D1 receptors modulate glutamate transmission in the ventral tegmental area. J Neurosci 1995; 15: 5379-88.
   Google Scholar
• Wolf ME, Xue CJ. Amphetamine and D1 dopamine receptor agonists produce biphasic effects on glutamate efflux in rat ventral tegmental area: modification by repeated amphetamine administration. J Neurochem 1998; 70: 198-209.
   Google Scholar
• Fitzgerald LW, Ortiz J, Hamedani AG, Nestler EJ. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral teg-mental area: common adaptations among cross-sensitizing agents. J Neurosci 1996; 16: 274-82.
   Google Scholar
• Roche KW, Tingley WG, Huganir RL. Glutamate receptor phosphorylation and synaptic plasticity. Curr Opin Neuro-biol 1994; 4: 383-8.
   Google Scholar
• Kalivas PW. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend 1995; 37: 95-100.
   Google Scholar
• Karler R, Calder LD, Chaudhry IA, Turkanis SA. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci 1989; 45: 599-606.
   Google Scholar
• Post RM, Weiss SR, Smith M, Rosen J, Frye M. Stress, conditioning, and the temporal aspects of affective disorders. Ann NY Acad Sci 1995; 771: 677-96.
   Google Scholar
• Moghaddam B. Stress preferentially increases extraneu-ronal levels ofexcitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993; 60: 1650-7.
   Google Scholar
• Takahata R, Moghaddam B. Glutamatergic regulation of basal and stimulus-activated dopamine release in the pre-frontal cortex. J Neurochem 1998; 71: 1443-9.
   Google Scholar
• Krystal JH, Moghaddam B, Breier A, Goldman-Rakic P, McElvey J. Glutamate, dopamine, the frontal cortex, and schizophrenia. Presented at the 53rd annual meeting of the Society of Biological Psychiatry, Toronto, May 1998.
   Google Scholar
• Alterman AI, Droba M, Antelo RE, Cornish JW, Sweeney KK, Parikh GA, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992; 31: 19-29.
   Google Scholar
• Tennant FS Jr, Sagherian AA. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Int Med 1987; 147: 109-12.
   Google Scholar
• Kosten TR, Morgan CM, Falcione J, Schottenfeld RS. Phar-macotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992; 49: 894-8.
   Google Scholar
• Kampman K, Volpicelli JR, Alterman A, Cornish J, Weinrieb R, Epperson L, et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend 1996; 41: 25-33.
   Google Scholar
• Robbins SJ, Ehrman RN, Childress AR, O'Brien CP. Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. Addict Behav 1992; 17: 491-9.
   Google Scholar
• White G, Lovinger DM, Peoples RW, Weight FF. Inhibition of W-methyl-D-aspartate activated ion current by desmethyl-imipramine. Brain Res 1990; 537: 337-9.
   Google Scholar
• Weddington WW Jr, Brown BS, Haertzen CA, Hess JM, Ma-haffey JR, Kolar AF, et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991; 17: 137-52.
   Google Scholar
• Kosten TR, Morgan CH, Schottenfeld RS. Amantadine and desipramine in the treatment of cocaine abusing methadone maintained patients. NIDARes Monogr 1991; 105: 510-1.
   Google Scholar
• Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of W-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the phar-macotherapy of depression. Pharmacopsychiatry 1996; 29: 23-6.
   Google Scholar
• Watanabe Y, Weiland NG, McEwen BS. Effects of adrenal steroid manipulations and repeated restraint stress on dy-norphin mRNA levels and excitatory amino acid receptor binding in hippocampus. Brain Res 1995; 680: 217-25.
   Google Scholar
• Nowak G, Redmond A, McNamara M, Paul IA. Swim stress increases the potency of glycine at the W-methyl-D-aspartate receptor complex. J Neurochem 1995; 64: 925-7.
   Google Scholar
• Yoneda Y, Han D, Ogita K. Preferential induction by stress of the W-methyl-D-aspartate recognition domain in discrete structures of rat brain. J Neurochem 1994; 63: 1863-71.
   Google Scholar
• Krugers HJ, Koolhaas JM, Bohus B, Korf J. A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area. Neurosci Lett 1993; 154: 73-7.
   Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990; 185: 1-10.
   Google Scholar
• Trullas R, Jackson B, Skolnick P. Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav 1989; 34: 313-6.
   Google Scholar
• Papp M, Moryl E. New evidence for the antidepressant activity ofMK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 1993; 45: 549-53.
   Google Scholar
• Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994; 263: 1-7.
   Google Scholar
• Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA. Adaptive changes in the W-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopro-panecarboxylic acid. J Pharmacol Exp Ther 1993; 265: 1380-6.
   Google Scholar
• Paul IA, Trullas R, Skolnick P, Nowak G. Down-regulation of cortical p-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology 1992; 106: 2857.
   Google Scholar
• Paul IA, Layer RT, Skolnick P, Nowak G. Adaptation of the NMDA receptor in rat cortex following chronic electrocon-vulsive shock or imipramine. Eur J Pharmacol 1993; 247: 305-11.
   Google Scholar
• Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the W-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994; 269: 95-102.
   Google Scholar
• Nowak G, Ordway GA, Paul IA. Alterations in the W-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675: 157-64.
   Google Scholar
• Cappello A, Charney DS, Berman R, Anand A, Miller H, Hen-inger GR, et al. NMDA receptor function in major depression. Presented at the 52nd annual meeting of the Society of Biological Psychiatry, San Diego, May 1997.
   Google Scholar
• Crane GE. Cycloserine as an antidepressant agent. Am J Psychiatry 1959; 115: 1025-6.
   Google Scholar
• Vale S, Espejel MA, Dominguez JC. Amantadine in depression [Letter]. Lancet 1971; 2: 437.
   Google Scholar
• Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 1990; 345: 716-8.
   Google Scholar
• Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res 1994; 655: 251-4.
   Google Scholar
• Sapolsky RM. Glucocorticoids, hippocampal damage and the glutamatergic synapse. Prog Brain Res 1990; 86: 13-23.
   Google Scholar
• Armanini MP, Hutchins C, Stein BA, Sapolsky RM. Gluco-corticoid endangerment of hippocampal neurons is NMDA-receptor dependent. Brain Res 1990; 532: 7-12.
   Google Scholar
• Elliott EM, Mattson MP, Vanderklish P, Lynch G, Chang I, Sapolsky RM. Corticosterone exacerbates kainate-induced alterations in hippocampal tau immunoreactivity and spectrin proteolysis in vivo. J Neurochem 1993; 61: 57-67.
   Google Scholar
• Elliott EM, Sapolsky RM. Corticosterone enhances kainic acid-induced calcium elevation in cultured hippocampal neurons. J Neurochem 1992; 59: 1033-40.
   Google Scholar
• Bremner JD, Randall P, Vermetten E, Staib L, Bronen RA, Mazure C, et al. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse— a preliminary report. Biol Psychiatry 1997; 41: 23-32.
   Google Scholar
• Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, et al. MRI-based measurement of hippocam-pal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 1995; 152: 973-81.
   Google Scholar
• Krystal JH, Bennett AL, Bremner JD, Southwick SM, Char-ney DS. Toward a cognitive neuroscience of dissociation and altered memory functions in post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobio-logical and clinical consequences of stress: from normal adaptation to posttraumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 239-69.
   Google Scholar
• Chambers AC, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and PTSD: toward a neurobiology of dissociation. Semin Clin Neuropsychiatry [In press].
   Google Scholar
• Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-52.
   Google Scholar
• Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
   Google Scholar
• Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-50.
   Google Scholar
• Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
   Google Scholar
• Konig P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996; 33: 80-4.
   Google Scholar
• Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients: a double-blind cross-over study. Br J Psychiatry 1995; 166: 241-3.
   Google Scholar
• DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599-602.
   Google Scholar
• Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: un-competitive antagonism. J Physiol 1997; 499: 27-46.
   Google Scholar
• Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M. Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 1993; 4: 687-90.
   Google Scholar
• Geter-Douglass B, Witkin JM. Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology 1997; 133: 43-50.
   Google Scholar
• Herrling P, ed. Excitatory amino acids: clinical results with antagonists. San Diego: Academic, 1997.
   Google Scholar
• Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135: 1081-4.
   Google Scholar
• Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Keta-mine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869-72.
   Google Scholar
• Warfel D, Lahti AC, Michaelidis T, Renwick H, Bean J, Weiler MA, et al. Follow-up patients who receive challenge with ketamine as a part of a research study. Presented at the 7th International Congress on Schizophrenia Research, Santa Fe, New Mexico, April 1999.
   Google Scholar
• Adler CM, Malhotra AK, Elman I, Carson R, Pickar D, Breier A. Effects of the W-methyl-D-aspartate receptor antagonist ketamine on striatal dopamine release in schizophrenia. Presented at the 7th International Congress on Schizophrenia Research, Santa Fe, New Mexico, April 1999.
   Google Scholar
• Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-7.
   Google Scholar
• Sklar GS, Zukin SR, Reilly TA. Adverse reactions to keta-mine anaesthesia: abolition by a psychological technique. Anaesthesia 1981; 36: 183-7.
   Google Scholar
• Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Presented at the 28th annual meeting of the Society for Neuroscience, Los Angeles, November 1998.
   Google Scholar
• Krystal J, Petrakis I, Krasnicki S, Trevisan L, Boutros N, D'Souza DC. Altered responses to agonists of the strychnine-insensitive glycine NMDA coagonist (SIGLY) site in recently detoxified alcoholics [Abstract]. Alcohol Clin Exp Res 1998; 22(3, suppl): 94A.
   Google Scholar